WO2005086870A2 - Nouvelles souches de lactobacille et procede d'utilisation correspondant - Google Patents
Nouvelles souches de lactobacille et procede d'utilisation correspondant Download PDFInfo
- Publication number
- WO2005086870A2 WO2005086870A2 PCT/US2005/007794 US2005007794W WO2005086870A2 WO 2005086870 A2 WO2005086870 A2 WO 2005086870A2 US 2005007794 W US2005007794 W US 2005007794W WO 2005086870 A2 WO2005086870 A2 WO 2005086870A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lactobacillus
- mbl
- ability
- hiv
- composition
- Prior art date
Links
- 241000186660 Lactobacillus Species 0.000 title claims abstract description 112
- 229940039696 lactobacillus Drugs 0.000 title claims abstract description 110
- 238000000034 method Methods 0.000 title claims abstract description 29
- 239000000203 mixture Substances 0.000 claims abstract description 22
- 210000004027 cell Anatomy 0.000 claims description 100
- 241000894006 Bacteria Species 0.000 claims description 37
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 31
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 31
- 241000700605 Viruses Species 0.000 claims description 30
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 28
- 208000031886 HIV Infections Diseases 0.000 claims description 18
- 230000001580 bacterial effect Effects 0.000 claims description 17
- 208000037357 HIV infectious disease Diseases 0.000 claims description 13
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 13
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 9
- 235000013406 prebiotics Nutrition 0.000 claims description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 6
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 208000004926 Bacterial Vaginosis Diseases 0.000 claims description 3
- 244000197813 Camelina sativa Species 0.000 claims description 3
- 241000222122 Candida albicans Species 0.000 claims description 3
- 241000222173 Candida parapsilosis Species 0.000 claims description 3
- 241000222178 Candida tropicalis Species 0.000 claims description 3
- 241000203734 Mobiluncus curtisii Species 0.000 claims description 3
- 241000235645 Pichia kudriavzevii Species 0.000 claims description 3
- 241000191967 Staphylococcus aureus Species 0.000 claims description 3
- 208000037009 Vaginitis bacterial Diseases 0.000 claims description 3
- 229940095731 candida albicans Drugs 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 235000015141 kefir Nutrition 0.000 claims description 3
- 108090000565 Capsid Proteins Proteins 0.000 claims description 2
- 210000002421 cell wall Anatomy 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108010087870 Mannose-Binding Lectin Proteins 0.000 abstract description 56
- 102000009112 Mannose-Binding Lectin Human genes 0.000 abstract description 56
- 241000725303 Human immunodeficiency virus Species 0.000 description 72
- 230000027455 binding Effects 0.000 description 27
- 208000015181 infectious disease Diseases 0.000 description 21
- 241000186840 Lactobacillus fermentum Species 0.000 description 14
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 14
- 244000052769 pathogen Species 0.000 description 14
- 239000002953 phosphate buffered saline Substances 0.000 description 14
- 241000713311 Simian immunodeficiency virus Species 0.000 description 13
- 108090000288 Glycoproteins Proteins 0.000 description 9
- 102000003886 Glycoproteins Human genes 0.000 description 9
- 102100021696 Syncytin-1 Human genes 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 229920001817 Agar Polymers 0.000 description 8
- 239000008272 agar Substances 0.000 description 8
- 235000020256 human milk Nutrition 0.000 description 8
- 210000004251 human milk Anatomy 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 101710121417 Envelope glycoprotein Proteins 0.000 description 7
- 238000004220 aggregation Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 208000030507 AIDS Diseases 0.000 description 6
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 6
- 230000002147 killing effect Effects 0.000 description 6
- 229940012969 lactobacillus fermentum Drugs 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 210000003370 receptor cell Anatomy 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 108060001084 Luciferase Proteins 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000006041 probiotic Substances 0.000 description 5
- 235000018291 probiotics Nutrition 0.000 description 5
- 210000002845 virion Anatomy 0.000 description 5
- 210000005253 yeast cell Anatomy 0.000 description 5
- 239000005089 Luciferase Substances 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 230000000529 probiotic effect Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000000527 sonication Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 210000001215 vagina Anatomy 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- 108010037897 DC-specific ICAM-3 grabbing nonintegrin Proteins 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 230000005526 G1 to G0 transition Effects 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 229960003276 erythromycin Drugs 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 230000002633 protecting effect Effects 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 241000606153 Chlamydia trachomatis Species 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001056128 Homo sapiens Mannose-binding protein C Proteins 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 229920000057 Mannan Polymers 0.000 description 2
- 102000015728 Mucins Human genes 0.000 description 2
- 108010063954 Mucins Proteins 0.000 description 2
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000012677 causal agent Substances 0.000 description 2
- 210000004970 cd4 cell Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 229940038705 chlamydia trachomatis Drugs 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 230000003641 microbiacidal effect Effects 0.000 description 2
- 229940124561 microbicide Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000006872 mrs medium Substances 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 239000001044 red dye Substances 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- RPAJSBKBKSSMLJ-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;hydrochloride Chemical class Cl.OC(=O)[C@@H](N)CCC(O)=O RPAJSBKBKSSMLJ-DFWYDOINSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 101100257133 Caenorhabditis elegans sma-3 gene Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000588697 Enterobacter cloacae Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000009338 Gastric Mucins Human genes 0.000 description 1
- 108010009066 Gastric Mucins Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 1
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 1
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000001698 Mannose-Binding Lectins Human genes 0.000 description 1
- 108010068997 Mannose-Binding Lectins Proteins 0.000 description 1
- PQMWYJDJHJQZDE-UHFFFAOYSA-M Methantheline bromide Chemical compound [Br-].C1=CC=C2C(C(=O)OCC[N+](C)(CC)CC)C3=CC=CC=C3OC2=C1 PQMWYJDJHJQZDE-UHFFFAOYSA-M 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102400001093 PAK-2p27 Human genes 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 101000749830 Rattus norvegicus Connector enhancer of kinase suppressor of ras 2 Proteins 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-PQMKYFCFSA-N alpha-D-mannose Chemical compound OC[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-PQMKYFCFSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000000959 cryoprotective effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 210000001526 defensive cell Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000000423 heterosexual effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 101150011109 mbl gene Proteins 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002855 microbicide agent Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 108010062490 p27 antigen Proteins 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229940098458 powder spray Drugs 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003253 viricidal effect Effects 0.000 description 1
- 244000000190 yeast pathogen Species 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/143—Fermentum
Definitions
- HIV human immunodeficiency virus
- AIDS acquired immune deficiency syndrome
- the present invention provides a method for altering the bacterial composition of the digestive tract or urogenital tract of a mammalian subject comprising administering to the subject bacteria of at least one MBL-positive Lactobacillus strain.
- the present invention provides a composition comprising MBL-positive Lactobacillus bacteria, the bacteria characterized by the ability to co- aggregate with Saccharomyces cerevisiae and to bind to gpl20.
- the present invention provides a method of evaluating a Lactobacillus isolate for its suitability for use in methods or compositions of the invention comprising testing the isolate for the ability to co-aggregate with a yeast, bacterium, or virus comprising mannose on its cell wall or envelope, the ability to bind a mannose containing viral coat protein, the ability to bind at least one HIV -target cell, or the ability to block HIV infection.
- Fig. 1 is an image of co-aggregating mannose binding lectin positive Lactobacillus and yeast.
- Fig. 2 is a graph showing the results of quantitative binding of various Lactobacillus isolates to immobilized gpl20.
- Fig. 3 is a graph showing the results of quantitative binding of Lactobacillus fermentum OLB 19a to viral envelop proteins form different clades of HIV and SIV.
- Fig. 4 is an image showing binding of mannose binding lectin positive Lactobacillus to HIV -target cells.
- Fig. 5 is a graph showing the number of HIV viruses bound as a function of the Lactobacillus cell concentration.
- Fig. 6 compares the number of HIV viruses trapped by an MBL-negative Lactobacillus and two MBL-positive Lactobacillus strains.
- Fig. 7 shows the relative fluorescence of Luciferase-tagged HIV present in a cell culture observed following infection with or without preincubation with a MBL- positive Lactobacillus in various concentrations.
- Fig. 8 shows the number of HIV virions in cells exposed to HIV in the presence of Lactobacillus OLB43b as a function of exposure time (Fig. 8A) and cell concentration (Fig. 8B).
- Fig. 9 shows the number of HIV or SIV virions bound by Lactobacillus cells as a function of Lactobacillus strain.
- Fig. 10 is an image showing the presence or absence of capture by MBL positive lactobaciUi to plain green fluorescent polystyrene beads (Fig. 10A) or gpl20- linked green fluorescent polystyrene beads (Fig. 10B). DETAILED DESCRIPTION
- Innate immunity is the first line of defense, and includes anatomic barriers, defensive cells, humoral factors, and commensal bacteria.
- Infants host a large number of commensal bacteria. Infants begin acquiring commensal bacteria during or after birth. It is envisioned that altering the composition of commensal bacteria of an infant's digestive tract may afford protection against infection by HIV or other pathogens. Similarly, altering the composition of commensal bacteria of the vagina may protect against HIV infection or other pathogens.
- HIV contains mannose in the glycoproteins of its envelope.
- the presence of mannose in the glycoproteins is fairly constant and relatively insensitive to antigenic shifts in HIV caused by mutational changes.
- Human mannose-binding lectin (MBL) is a plasma protein that binds to mannose-containing microorganisms, including viruses, bacteria, fungi, and protozoa. Binding of mannose-containing pathogens by MBL facilitates clearance of the pathogen by complement activation and opsonization, and subsequent phagocytosis.
- human MBL is found principally, if not exclusively, in the plasma, it does not provide infants with a first line of defense at the site of infection, specifically, in the digestive tract.
- Lactobacillus strains were isolated from saliva of apparently healthy human subjects and tested for the ability to coaggregate with Saccharomyces cerevisae (baker's yeast), a yeast containing mannose. Of the tested strains, nine were found to co-aggregate with S. cerevisae. The addition of mannose at concentrations of 50 mM or 100 mM prevented or reversed Lactobacillus co-aggregation with S. cerevisae.
- Lactobacillus strains having the ability to co-aggregate with S. cerevisae are referred to herein as MBL-positive Lactobacillus strains.
- Transposon mutants of a MBL positive Lactobacillus fermentum strain OLB- 19a were created and a putative MBL disruption mutant was selected on the basis of its inability to bind yeast, and designated TM-4A3.
- the region of the chromosome of TM- 4A3 into which the transposon was inserted has been subcloned and sequencing of that region of the putative MBL disruption mutant is currently under way.
- the nine Lactobacillus strains capable of co- aggregating S. cerevisae were evaluated for the ability to bind to the HIV envelope glycoproteins gpl20 from strain SF2.
- Six strains (OLB- 12, OLB- 19a, OLB-24b, OLB- 36b, OLB-43b, and 101S) were found to bind to gpl20.
- the mutant TM-4A3 does not bind to gpl20.
- OLB- 19a which was found to bind to gpl20 with a relatively high affinity, was further tested and found to bind to envelope glycoproteins from several different clades of HIV or simian immunodeficiency virus (SIV).
- the six gpl20-binding strains were assigned to three different species based on 16S rRNA gene analysis as follows: OLB-19a and 101S belong to L. fermentum; OLB-24b belongs to L. gallinarium; and OLB- 12, OLB-36b, and OLB-43b belong to L. delbrueckii subsp. lactis.
- the glycoprotein of interest was immobilized in the wells of a microtiter plate, the glycoprotein was contacted with cells of a test bacterial strain, unbound cells were removed by washing, bound cells were removed by elution with mannose, and the cells were plated and counted.
- the HIV glycoprotein was immobilized on a glass slide, contacted with cells of a test bacterial strain, washed and Gram-stained to visually detect bacteria bound to the slide through the glycoprotein. It is envisioned that any suitable means may be used in screening Lactobacillus isolates for the ability to bind to HIV envelope glycoproteins.
- virus capture ELISA demonstrated that both Lactobacillus OLB- 19a and OLB-43b bind to free HIV-l Ba virus in a dose-dependent manner, and that OLB- 19a binds more free HIV than OLB-43b binds.
- OLB- 19a was found to bind all HIV target cell types tested, including T and B lymphocytes, monocytes, and cells expressing DC- SIGN. The binding was reversible upon addition of 50 mM mannose.
- OLB-43b affords greater protection against infection by HIV in a dose-dependent manner.
- the protective effect may be due to factors that destroy HIV viruses, such as secreted or surface-bound MBL or proteinases.
- vaginal MBL positive Lactobacillus isolates were characterized with respect to various properties, including yeast binding, gpl20 binding, HIV trapping, and inhibiting the growth of yeast or pathogenic bacteria. It is envisioned that isolates having desirable characteristics may be used to alter the composition of bacteria present in the vagina. This may afford protection against viruses such as HIV, yeast, or pathogen bacteria. The protection may be transient or extended over time, depending on the length of time the MBL positive Lactobacillus strains persist.
- MBL positive Lactobacillus strain used alone will afford protection against pathogens
- more than one MBL positive Lactobacillus strain may be used in combination.
- such combinations may include a Lactobacillus strain or strains having a surface bound MBL and a Lactobacillus strain that secrets MBL.
- a strain such as OLB- 19a may be used in combination with a strain such as OLB-43b.
- Oral Lactobacillus strains producing MBL have been shown to reduce the ability of HIV contacted with the strains to infect HIV target cells.
- the ability of a MBL positive Lactobacillus strain to reduce infectivity of HIV may be associated with its mannose binding activity. It is therefore reasonably expected that the Lactobacillus strains will also afford protection against or reduce colonization of the digestive tract or infection by other mannose or MBL-like adhesin containing organisms, including, but not limited to, pathogenic E.
- coli Salmonella species, Vibrio cholerae, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter cloacae, Candida species, Aspergillus fumigatus, Cryptosoporidium parvum, Neisseria meningitidis, Neisseria gonorrhoeae, Chlamydia trachomatis, rotaviruses, hepatitis B, hepatitis C, herpes simplex, Nipah (a causal agent of fatal hemorrhagic encephalitis), ⁇ bola, and influenza A and B viruses.
- Lactobacillus strains described in the Examples are of oral or vaginal origin, it is specifically envisioned that Lactobacillus strains isolated from other sources (e.g., milk) would be useful in the practice of the present invention.
- Lactobacillus isolates suitable for use in the present invention that may be identified by screening using any suitable assay, including, but not limited to, those described herein.
- a Lactobacillus isolate can be evaluated for putative MBL activity using coaggregation assays, binding to a mannose-containing glycoprotein, or by binding to yeast.
- the ability to bind to HIV target cells or to free viruses, or to protect HIV target cells can be assayed as described herein, or using any other suitable assay.
- Lactobacillus fermentum OLB- 19a and L. delbureckii subsp. lactis. OLB-43b were deposited under the terms of the Budapest treaty with the American Type Culture Collection in Manassas, VA on March 5, 2004 as ATCC accession numbers PTA-5849 and PTA-5850, respectively.
- the present invention includes derivatives of Lactobacillus fermentum OLB- 19a and L. delbureckii subsp. lactis. OLB-43b.
- a derivative of a Lactobacillus strain is an organism that is selected, mutagenized, genetically engineered or otherwise obtained from that strain.
- an MBL positive Lactobacillus strain or strains may be delivered as a probiotic shortly after birth to an infant at risk of orally contracting HIV or other pathogens containing mannose or MBL-like adhesins through breast milk or contaminated water or any other means.
- Human T-cell lymphotropic virus can also be transmitted from mother to child through breast milk, including colostrum, presumably through T-lymphocytes infected with the virus present in breast milk. It is likely that hepatitis may also be present in breast milk of infected women.
- the bacteria Prior to administration, the bacteria may be lyophilized and stored in the lyophilized form, and reconstituted just prior to administration with an acceptable carrier, such as sterile water or breast milk, and delivered in an amount effective to establish colonization.
- the Lactobacillus may be delivered as a symbiotic in conjunction with one or more prebiotics.
- Prebiotics are carbohydrates that are used probiotic bacterium, but are not substantially used by the host or other bacteria present. Symbiotics are a preferred formulation, because the added prebiotic sugar or sugars can promote the growth and colonization of the probiotics. Because trehalose can be used by many bacteria, it is not suitable as a prebiotic.
- Glucono-delton-lactone (GDL) can be utilized by OLB 19a, and mannitol can be utilized by OLB43b, but neither can be used by the host and by most other bacteria. Therefore, these two sugars are prebiotics for these lactobaciUi.
- GDL is a natural constituent of many foods and mannitol is an edible food additive. Both GDL and mannitol are generally regarded as safe (GRAS) by FDA.
- Agarwal et al. describes the delivery of Lactobacillus rhamnosus strain GG to low birth weight neonates for use as a probiotic.
- Agarwal et al. describes using twice daily doses of 10 9 organisms for eight days for newborns receiving antibiotics. It is envisioned that fewer doses may be necessary for infants not on antibiotics.
- Colonization may be evaluated by performing colony counts on stool samples. It is envisioned that it would be preferable to deliver the bacteria to the infant as soon as possible after birth. Infants receiving the bacteria later may require more doses to effectively colonize the digestive tract. An infant may require an additional dose or doses following a course of antibiotics.
- MBL-producing Lactobacillus strains may be used in a subject of any age to colonize the digestive tract, vagina or rectum and may serve as a barrier to infection by mannose or MBL-like adhesin containing pathogens through those routes. Colonization of the vagina may be especially useful in protecting against infection by HIV, hepatitis B, hepatitis C, herpes simplex, E. coli, Neisseria gonorrhoeae, and Chlamydia trachomatis, or in preventing or treating bacterial vaginosis or vaginal candidiasis.
- the Lactobacillus may be provided in any suitable form, including, but not limited to, lyophilized form as a powder for direct ingestion or for ingestion following reconstitution, as a powder spray, as nipple cream, in capsule form, as a rectal or vaginal suppository, in feminine hygiene products such as tampons, as a candy-like product, as a nasal spray, or in food, such as yogurt.
- the Lactobacillus may be provided as a pharmaceutical composition with a pharmaceutically acceptable carrier or excipient.
- the present invention would be suitable for use in economically important species other than humans, including livestock, or in species that serve as reservoirs of disease.
- diarrhea in cattle caused by mannose or MBL-like adhesin containing pathogens may be reduced by colonizing the gut of cattle with an MBL-positive Lactobacillus.
- the Lactobacillus strains could be delivered in liquid form by reconstituted lyosphilized bacteria, in a capsule, or mixed with feed.
- an isolated MBL protein from a Lactobacillus strain to the nasal passages may confer protection against or treat infections acquired through that route or respiratory tract or lungs infections, such as influenza, Klebsiella, or Pseudomonas.
- the putative cloned MBL coding sequence will allow construction of an expression vector that will facilitate isolation of the MBL polypeptide sequence, which can be purified for nasal or oral delivery to subjects at risk of infection or infected with influenza or diarrhea caused by mannose or MBL-like adhesin containing pathogens.
- the purified MBL could be delivered vaginally before or after intercourse to inactivate mannose or MBL-like adhesin containing pathogens associated with sexually transmitted disease.
- Saliva was aseptically collected from healthy human subjects and plated on the Lactobacillus Rogosa (Difco) agar plates and incubated at 37°C for 24-48 h anaerobically. For liquid cultures, a single colony was transferred to Lactobacillus MRS broth incubated at 37°C for 16-24 h. When required, the culture was stored at -70°C with 15% glycerol.
- Lactobacillus cells (10 7 /10 ⁇ l) from cultures of late log or stationary phase were washed with phosphate-buffered saline (PBS) and combined on a glass slide with Saccharomyces cerevisiae (10 6 /10 ⁇ l) grown in YPD broth at 37°C for 24 h and harvested similarly by resuspending in PBS.
- the bacterium and yeast mixture was incubated for 10 min at room temperature. The cells were observed under a light microscope to detect the presence or absence of coaggregation of the bacteria and yeast cells.
- Representative results obtained with Lactobacillus fermentum OLB- 19a are shown in Fig. 1.
- Panel A shows OLB- 19a alone
- panel B shows S.
- panel C shows OLB- 19a and S. cerevisiae
- panel D shows a OLB- 19a and S. cerevisiae in the presence of mannose (50 mM).
- Lactobacillus fermentum OLB- 19a causes clumping of yeast cells (Fig. 1C), which does not occur in the presence of 50 mM mannose (Fig. ID).
- the Gram-positive temperature-sensitive transposon-like plasmid pGh9:ISS7 was used to mutagenize the MBL + strain L. fermentum OLB- 19a.
- the plasmid was transformed into OLB- 19a by electroporation (Wei et al, 1995).
- the transformants were selected on MRS agar plates supplemented with 5 ⁇ g/ml erythromycin at 28°C for 48 - 72 h in a candle jar.
- the transformants were tested for plasmid integration rate by replica-plating with one plate incubated at 42°C and the other at 28°C.
- a transformant displayed a 1% plasmid integration rate at 42°C was selected for further studies. Mutagenesis was achieved by shifting a mid-exponential phase culture (10 ml) from 28°C to 42°C for 2 h without antibiotic selection, and subsequently plating on MRS agar plates supplemented with 5 ⁇ g/ml erythromycin and incubating at 37°C.
- the red dye-stained yeast cells were extensively washed with PBS until the supernatant became clear. Mutant Lactobacillus clones were grown overnight in MRS broth in microtiter plates and transferred to nitrocellulose membranes. The bacterial cells were dried at room temperature and soaked in PBS. The red dye-stained yeast was used as a probe to react with the bacterial blot on the nitrocellulose membranes in a plastic pouch for 1 h on a rocker at room temperature. The membrane was extensively washed with PBS to remove unbound yeast. Among all tested mutants, only one, Tm-4A3, failed to bind the red dye- stained yeast. This mutant was used as a negative control isogenic MBL-negative strain for subsequent experiments.
- the plasmid-tagged MBL gene was cloned in E. coli by isolating the mutant DNA, self-ligation, transformation of E. coli and selection of erythromycin resistant transformants at 28°C.
- the DNA sequence of the cloned pGh9:ISS7 inserted gene is currently being determined.
- Lactobacillus strains that co-aggregated with yeasts were tested for their binding to HIV envelope proteins.
- the envelope protein (NIH AIDS Research and Reference Reagent Program, Cat# 386) of one representative strain, HIV-1 SF2 , was used for initial selection.
- Overnight cultures of nine oral Lactobacillus strains and ten vaginal strains in MRS were harvested by centrifugation and washed twice with PBS and resuspended in PBS. The cells were subjected to brief sonication by a microsonic cell disrupter ( Komtes, Model KT50) to break clumps.
- a microsonic cell disrupter Komtes, Model KT50
- a 100 ⁇ l cell suspension (about 10 cells) was added, in triplates, to each well of microtiter plate pre-coated with 0.2 ⁇ g HIV- 1SF 2 gpl20.
- the wells pre-coated with porcine gastric mucin were used as a negative control glycoprotein.
- the isogenic MBL-negative mutant Tm-4A3 was used as a negative control Lactobacillus strain.
- the microtiter plates were incubated for 20 min at room temperature. The unbound cells were removed by washing with PBS five times. The bound cells were eluted with 50 mM mannose and plated on MRS agar with serial dilutions for colony counts. Binding was also tested on protein coated glass slides.
- MBL positive Lactobacillus strain OLB- 19a and its isogenic MBL- knockout mutant TM-4A3 were tested for the ability to bind to HIV envelope glycoproteins from various HIV or simian immunodeficiency virus (SIV) clades on microtiter plates, essentially as described in the previous section, or on glass slides that were first coated with protein, reacted with lactobaciUi, washed, and visualized by Gram staining.
- SIV simian immunodeficiency virus
- the viral envelope proteins were all obtained from NIH AIDS Research and Reference Reagent Program, including gpl20s of HIV CM235 (Cat# 2698), HIV Ba L (Cat# 4961), HIV S FI 6 2, (Cat# 7363) HIV SF 2 (Cat# 386), HIV.,TM (Cat# 4683), HIV C ⁇ ad eE (Cat# 3234), and HIV CN54 (Cat# 7749); gpl30 of SIV MaC239 (Cat# 2322); and gpl40 of SIV Mac i A ii (Cat# 2209).
- HIV can be transmitted by cell-free or cell-associated viruses
- HIV-infected cells such as the CD4 T- lymphocytes, in milk or semen, co-aggregate with bacteria, the cells will be trapped, thus reducing contact with HIV-target cells and cell-associated viral infection.
- Three oral Lactobacillus strains (OLB- 19a, OLB-43b and Tm-4A3) were tested for co-aggregation with cell lines representing different HIV-target cells, including T lymphocytes (HPB-ALL-CD4, Jurket, CEMl, and CEM2), B lymphocytes (Jy), and monocytes (THP-J, THP-DC-SIGN, and U937), with and without 10 mM CaCl and/or 50 mM mannose.
- the cells were cultured in RPMI-1640 medium (MediaTech, Cat# 10-040- CV).
- OLB- 19a co-aggregated with all the HIV-target cells tested.
- OLB-43b and the MBL mutant strain Tm-4A3 did not co-aggregate with any of these cells.
- the co-aggregation between OLB— 19a and these HIV-target cells was blocked or reversed by 50 mM mannose or alpha-D-mannoside.
- the cells were maintained on ice for about 1-2 h before mixing with HIV viruses.
- Different concentrations of HIV-l ⁇ aL viruses (up to 2.1 x 10 /virion 50 ⁇ l) and Lactobacillus cells were mixed in the cell culture medium (without antibiotics) and incubated at 37°C for 1 h.
- the bacterial cells were centrifuged for 5 min at 3000 xg and the pellet were assayed for bound HIV by the virus-capture p24 ELISA (Perkin Elmer, Cat# NEK050001KT).
- the number of bound HIV was plotted as a function of the number of OLB- 19a cells (Fig. 5).
- the number of virions bound is shown as a function of cell type (Fig. 6A), with OLB- 19a binding more than OLB-43b.
- PBMC peripheral blood mononuclear cells
- OLB- 19a cells were found to bind more HIV viruses, OLB-43b afforded greater protection of cells from infection with HIV (Fig. 6B). Increased HIV killing by OLB-43b may be due to secreted MBL and/or other potential viricidal acitivities, such as proteinase, acid and hydrogen peroxide.
- Luciferase-tagged HIV can be used to monitor the rate of HIV infection because the infected cells will express the enzyme luciferase and will glow.
- the 293T cells were co-transfected with the pHXB2 and pNL4-3.Luc.R-E- plasmids (catalog # 1069 and 3418; NIH AIDS Research and Reference Reagent Program) to produce luciferase-tagged HIV-l H ⁇ B2 viruses, which were used to infect U87 (U87.CD4.CXCR4: catalog# 4036) receptor cells after interacting with lactobaciUi. Briefly, 293T cells were seeded to 4x10 cells per 100 mm plate the day before transfection.
- the virus was aspirated and replaced with U87 medium (Dulbecco's modification of Eagle's medium, Cat# 10-013-CV, MediaTech) and the cells were allowed to rest for another 24 h.
- U87 medium Dulbecco's modification of Eagle's medium, Cat# 10-013-CV, MediaTech
- the luciferase activity was measured in triplicate using the Luciferase Assay System from Promega (cat# E4030) and a Berthold FBI 2 luminometer running Sirius software.
- the lactobaciUi were grown 37°C in MRS broth overnight to reach stationary phase.
- the cells were washed with the receptor cell U87 medium and resuspended in 10% of its original volume (about 10 9 cells/ml).
- OLB- 19a cells were subjected to a brief sonication to break up clumps.
- the viruses (1 :16 dilution) and the MBL+ strains OLB- 19a, OLB-43b, or the MBL mutant strain Tm4A3 were mixed in equal volumes with the bacteria being diluted to varying concentrations (1 :2 through 1 :8) in the receptor cell media.
- This medium contained 100 unit/ml penicillin G and 200 ⁇ g/ml streptomycin, which prevented growth of the lactobaciUi.
- These samples of virus and bacteria were rocked gently at room temperature for 20 minutes and incubated on the bench for another 40 minutes. The samples were then centrifuged at 10,000 x g for 3 minutes and filtered through a 0.45 ⁇ m filter, added at 400 ⁇ l to the receptor cells, which was seeded the day before in a 12-well-plate to lxlO 4 cells per ml, and incubated at 37°C in a CO 2 incubator overnight. The following morning, new media was added to the cells.
- luciferase activity (Luciferase assay kit E4030, Promega, Madison, WI) according to the manufacturer's instructions.
- the luciferase readout was performed in triplicate at a tenfold dilution of receptor cell lysate on a triplicate set of infected receptor cells. The average of the luciferase triplicate readout was used as the output for each of the experiments and the triplicate of these experiments is used to calculate the standard deviation.
- the results of inhibition of HIV infection by Lactobacillus strains are summarized in the bar graph shown in Fig. 7.
- the Y axis shows the relative light units, which is correlated with HIV infection.
- a comparison of a control infection (the first bar) is virus alone without the addition of bacteria..
- OLB- 19a and mutant TM4A3 did not afford significant protection of the cells against the free virus.
- OLB-43b afforded dose-dependent protection of cells against HIV even at the highest tested dilution (1:8).
- the cells were maintained on ice for about 1-2 h before mixing with HIV or SIV viruses.
- Different concentrations of HIV-2 or SIV viruses up to 2.1 x 10 8 /virion/50 ⁇ l
- Lactobacillus cells were mixed in the cell culture medium (without antibiotics) and incubated at 37°C for 1 h.
- the bacterial cells were centrifuged for 5 min at 3000 xg and the pellet were assayed for bound HIV-2 or SIV by the virus-capture p27 antigen ELISA using RETRO-TEK SIV (Zeptometrix, Catalog # 0801169).
- a mock HIV model was constructed by cross-linking HIV-1 S F2 gpl20 to green fluorescent polystyrene beads (0.8 ⁇ m) (Spherotech, Inc., Libertyville, Illinois, USA) and mixed with isopropanol- killed, red fluorescence-stained L. fermentum OLB 19a cells (Live/Dead Stain, Molecular Probes, Eugene, Oregon, USA).
- a fluorescent Olympus camera microscope was used to observe capture of mock HIV by red fluorescence stained lactobaciUi.
- vaginal lactobacillus isolates were screened for co-aggregation of yeast as described above, and 26 isolates were found to bind yeast. Those 26 isolates were evaluated essentially as described above for the oral lactobacillus isolates. Twelve were found to adhere to gpl20-coated plates. These strains were subsequently tested for ability to block HIV-1 infections and to coaggregate with HIV-target cells, CD4+ ALL T lymphocytes and DC-SIGN+ monocytes as described above. Eight strains were found to block HIV-1 infection.
- the five vaginal strains and six oral strains of Lactobacillus were further evaluated for the ability to protect against infection by bacterial vaginosis-associated bacteria (Esherichia coli ATCC14243, Staphylococcus aureus ATCC25923, Pseudomonas aeruginosa ATCC27853, Gardnerrella vaginalis ATCC14018, Gardnerrella vaginalis ATCC49145, and Mobiluncus curtisii subsp curtisii ATCC35241), or yeast associated with vaginal infections (Candida albicans ATCC 10231, C. krusei ATCC 14242, C. glabrata ATCC66032, C.
- Lactobacillus OLB 19a The ability of Lactobacillus OLB 19a to inhibit fungal growth was further evaluated as follows.
- the Lactobacillus OLB 19a culture was streaked in two parallel lines on a square MRS plate and incubated overnight at 37°C.
- a MBL negative strain, Lactobacillus OLB21a was substituted for Lactobacillus OLB 19a in a parallel experiment.
- Cultures of each of the six Candida isolates were spotted between the two Lactobacillus streaks, and at the far side of the plate, and incubated overnight. Inhibition of the yeast was observed by comparing the yeast drops in the two places on the same agar plate. The percentage inhibition was estimated by visually comparing yeast growth at the two sites at which the cultures were spotted.
- Lyophilized preparations of select Lactobacillus strains were made as follows. Each bacterial strain was grown in 500 ml MRS broth to the stationary phase (about 16 h). The cells were harvested and washed once with phosphate-buffered saline, repelleted, and the pellet was resuspended in 5 ml 10% trehalose, sucrose, cellobiose, lactose or glucono-delton-lactone (GDL). The cell suspension was frozen at -80°C for 1 hour in a lyophilizing bottle. The freeze-drying was conducted with a Labconco Lyophilizer for about 20 h.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55189004P | 2004-03-10 | 2004-03-10 | |
US60/551,890 | 2004-03-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005086870A2 true WO2005086870A2 (fr) | 2005-09-22 |
WO2005086870A3 WO2005086870A3 (fr) | 2006-10-05 |
Family
ID=34976202
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/007794 WO2005086870A2 (fr) | 2004-03-10 | 2005-03-10 | Nouvelles souches de lactobacille et procede d'utilisation correspondant |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2005086870A2 (fr) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2087094A1 (fr) * | 2006-11-17 | 2009-08-12 | SCA Hygiene Products AB | Lactobacillus fermentum ess-1, dsm17851 et son utilisation pour le traitement et/ou la prévention de la candidose et des infections des voies urinaires |
US9125768B2 (en) | 2006-11-17 | 2015-09-08 | Sca Hygiene Products Ab | Hygiene tissue comprising a microbe-inhibiting composition |
US9283297B2 (en) | 2006-11-17 | 2016-03-15 | Sca Hygiene Products Ab | Sanitary article comprising a microbe-inhibiting composition |
CN110680836A (zh) * | 2018-06-19 | 2020-01-14 | 景岳生物科技(中国)有限公司 | 副干酪乳杆菌菌株gmnl-653用于制备改善狐臭组合物的用途 |
CN110804571A (zh) * | 2019-12-02 | 2020-02-18 | 华中农业大学 | 一种复合乳酸菌制剂及在制备成饲料添加剂中的应用 |
EP4130258A1 (fr) * | 2021-08-02 | 2023-02-08 | Evonik Operations GmbH | Micro-organismes affichant des récepteurs leurres viraux |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6159465A (en) * | 1995-03-23 | 2000-12-12 | Probi Ab | Epithelial adhesive lactobacilli |
-
2005
- 2005-03-10 WO PCT/US2005/007794 patent/WO2005086870A2/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6159465A (en) * | 1995-03-23 | 2000-12-12 | Probi Ab | Epithelial adhesive lactobacilli |
Non-Patent Citations (2)
Title |
---|
ADLERBERTH I. ET AL.: 'A Mannose-Specific Adherence Mechanism in Lactobacillus plantarum Conferring Binding to the Human Colonic Cell Line HT-29' APPLIED AND ENVIRONMENTAL MICROBIOLOGY vol. 62, no. 7, July 1996, pages 2244 - 2251, XP002979206 * |
CHANG ET AL.: 'Inhibition of HIV Infectivity by a Natural Human Isolate of Lactobacillus jensenii Engineered to Express Functional Two-Domain CD4' PNAS vol. 100, no. 20, September 2003, pages 11672 - 11677, XP002371508 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2087094A1 (fr) * | 2006-11-17 | 2009-08-12 | SCA Hygiene Products AB | Lactobacillus fermentum ess-1, dsm17851 et son utilisation pour le traitement et/ou la prévention de la candidose et des infections des voies urinaires |
JP2010509911A (ja) * | 2006-11-17 | 2010-04-02 | エスセーアー・ハイジーン・プロダクツ・アーベー | カンジダ症及び尿路感染の予防及び/または治療のための発酵乳酸桿菌Ess−1、DSM17851及びそれの使用 |
EP2087094A4 (fr) * | 2006-11-17 | 2010-10-06 | Sca Hygiene Prod Ab | Lactobacillus fermentum ess-1, dsm17851 et son utilisation pour le traitement et/ou la prévention de la candidose et des infections des voies urinaires |
US8222020B2 (en) | 2006-11-17 | 2012-07-17 | Sca Hygiene Products Ab | Biologically pure strain of Lactobacillus fermentum, strain Ess-1 |
US9125768B2 (en) | 2006-11-17 | 2015-09-08 | Sca Hygiene Products Ab | Hygiene tissue comprising a microbe-inhibiting composition |
US9283297B2 (en) | 2006-11-17 | 2016-03-15 | Sca Hygiene Products Ab | Sanitary article comprising a microbe-inhibiting composition |
CN110680836A (zh) * | 2018-06-19 | 2020-01-14 | 景岳生物科技(中国)有限公司 | 副干酪乳杆菌菌株gmnl-653用于制备改善狐臭组合物的用途 |
CN110680836B (zh) * | 2018-06-19 | 2021-04-02 | 景岳生物科技(中国)有限公司 | 副干酪乳杆菌菌株gmnl-653用于制备改善狐臭组合物的用途 |
CN110804571A (zh) * | 2019-12-02 | 2020-02-18 | 华中农业大学 | 一种复合乳酸菌制剂及在制备成饲料添加剂中的应用 |
EP4130258A1 (fr) * | 2021-08-02 | 2023-02-08 | Evonik Operations GmbH | Micro-organismes affichant des récepteurs leurres viraux |
WO2023011828A1 (fr) * | 2021-08-02 | 2023-02-09 | Evonik Operations Gmbh | Micro-organismes présentant des récepteurs leurres viraux |
Also Published As
Publication number | Publication date |
---|---|
WO2005086870A3 (fr) | 2006-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Coconnier et al. | Antibacterial effect of the adhering human Lactobacillus acidophilus strain LB | |
KR101683474B1 (ko) | 과민성 대장 증후군 예방 또는 치료용 조성물 | |
KR101473058B1 (ko) | 과민성 대장 증후군 예방 또는 치료용 조성물 | |
TWI459951B (zh) | 新穎噬菌體及含該噬菌體之抗菌組成物 | |
RU2551315C2 (ru) | Выделение, идентификация и характеристика штаммов с пробиотической активностью, выделенных из фекалий детей, вскармливаемых исключительно материнским молоком | |
EP2179028B1 (fr) | Nouvelle souche de bifidobactérie et peptides actifs contre des infections par un rotavirus | |
CN107250352B (zh) | 新型肠致病性大肠杆菌噬菌体Esc-CHP-2及其用于抑制肠致病性大肠杆菌增殖的用途 | |
US8632766B2 (en) | Strain composition of the Lactobacillus genus and the application of strain composition of the Lactobacillus genus | |
RU2567009C2 (ru) | ШТАММ Lactococcus lactis ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАССТРОЙСТВА ПИЩЕВАРЕНИЯ И ЕГО ПРИМЕНЕНИЕ | |
US8349586B1 (en) | Commensal strain of E. coli encoding an HIV GP41 protein | |
KR20230132886A (ko) | 비브리오 종에 의한 감염을 예방하기 위한 방법 및 조성물 | |
JP2015061882A (ja) | 共生乳酸産生細菌およびその使用 | |
WO2005086870A2 (fr) | Nouvelles souches de lactobacille et procede d'utilisation correspondant | |
WO2019227418A1 (fr) | Composition et ses applications | |
JP2016533744A (ja) | プロバイオティクスとしてのラクトバチルス属の菌株 | |
KR20160005728A (ko) | 박테리오파지 테라피 | |
US20230321163A1 (en) | Composition For Treating or Preventing Clostridium Difficile Infection | |
US20130202571A1 (en) | Use of probiotic bacteria to prevent and treat listerial infections | |
KR20200123128A (ko) | 병원성 박테리아 | |
CN112029676B (zh) | 一种有利于提高免疫力的益生菌组合及其应用 | |
WO2019227414A1 (fr) | Composition et ses applications | |
KR20170031516A (ko) | 살모넬라, 병원성 대장균 o157 및 이질균에 대해 동시에 숙주감수성을 나타내는 박테리오파지 bsp10 및 이를 함유하는 조성물 | |
EP2742125B1 (fr) | Souche de lactobacillus bulgaricus qui empeche l'adhesion de helicobacter pylori aux cellules epitheliales | |
JP2001002578A (ja) | Helicobacterpylori除菌性医薬品 | |
WO2007023912A1 (fr) | Bifidobactérie inhibant l’adhésion de microbes pathogènes aux cellules, produit traité correspondant et compositions alimentaires et médicinales contenant ladite bifidobactérie |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |